Pfizer will pay $330 million upfront for ex-China rights to three preclinical in vivo CAR-T programs from Starna Therapeutics. The agreement includes up to $2.3 billion in milestones plus royalties, and Pfizer plans to lead development outside Greater China.

Diagnostics

Categories